Listed by the USPTO as CARTER, SANDRA DILLAHUNT
Tech Center 1600 • Art Units: 1646 1674 1699
This examiner grants 56% of resolved cases
CARTER, SANDRA DILLAHUNT is a USPTO patent examiner in tech center 1600 and art unit 1646. The record covers 532 resolved cases, with an allowance rate of 56.2% and a median of 1283 days to allowance. The interview lift is 28.6%, showing a meaningful association between interviews and allowance outcomes in a record with a moderate overall allowance rate.
The listed companies are The Trustees of the University of Pennsylvania, Xencor Inc., and Novartis AG. Representative firms include HOWSON & HOWSON LLP, MAIER & MAIER, PLLC, and MCCARTER & ENGLISH, LLP BOSTON. Practitioners should prepare for substantive examiner discussions while allowing for a lengthy prosecution timeline.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18628097 | METHODS OF TREATING NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS USING INTERLEUKIN-17 (IL-17) ANTAGONISTS | Non-Final OA | Novartis AG |
| 18246604 | METHODS AND COMPOSITIONS FOR IN SITU IMMUNE PROFILING OF HEART TRANSPLANT BIOPSIES | Non-Final OA | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 17908415 | PROTEIN NANOPARTICLE DESIGN AND APPLICATION | Final Rejection | Duke University |
| 17784186 | NOVEL INTERLEUKIN-15 (IL-15) FUSION PROTEINS AND USES THEREOF | Final Rejection | Cugene Inc |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy56.2% of resolved applications examined by Sandra Dillahunt Carter were allowed (532 resolved cases), compared with 40.9% across Art Unit 1646 over the last five years.
This examiner's interview lift is +28.6 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Sandra Dillahunt Carter took 1,283 days on average from filing to allowance.
Sandra Dillahunt Carter examines applications in Art Unit 1646 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
